Journals / Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2009 / Cilt: 49 - Sayı: 1

The relationship between hormone replacement therapy (HRT) and breast cancer with reference to NIH-WHI and million women studies: Current reviev

NIH-WHI ve milyon kadın çalışmalarının sonuçları ışığında hormon replasman tedavisi (HRT) ve meme kanseri ilişkisi

Pages
61–66
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

HRT should be employed with lowest effective dose and for the shortest period in treatment of menopausal symptoms.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The most efficient way of treating menopausal symptoms is hormone replacement therapy (HRT).
📊
Key Findings & Data:It hasbeen suggested that the long-term use may increase breast cancer risk, and most of the studies on HRT has focused on this subject.
💡
Conclusion & Impact:HRT should be employed with lowest effective dose and for the shortest period in treatment of menopausal symptoms.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The most efficient way of treating menopausal symptoms is hormone replacement therapy (HRT). It hasbeen suggested that the long-term use may increase breast cancer risk, and most of the studies on HRT has focused on this subject. The stable increase in the incidence of breast cancer leaded a limited and cautious use of HRT. WHI and Million Women studies, the most current and wide studies, caused a revoluti- on in this field. In the present study, a review from past to the current views was done. The results of our revi- ew showed that even HRT can be used for vasomotor symptoms, vaginal atrophy and osteoporosis, it should not be used as a treatment of a chronic condition. HRT should be employed with lowest effective dose and for the shortest period in treatment of menopausal symptoms.

Özet

Menopoz semptomlarının tedavisinde kullanılan en geçerli yol hormon replasman tedavisi (HRT) dir. Özellikle uzun süreli kullanımla meme kanseri riskini artırdığı yolunda iddialar ortaya atılmış, HRT ile ilgili yapılan çalışmaların büyük çoğunluğu bu konu üzerinde yoğunlaşmıştır. Meme kanseri insidansında görülen sürekli artış, menopoz semptomlarının tedavisinde HRT kullanımını da kısıtlamaktadır. Bu alanda yapılan en yeni ve geniş kapsamlı çalışmalar WHI ve Milyon Kadın çalışmaları olup sonuçları devrim yaratacak boyutta olmuştur. Tarihsel olarak ele alıp bugüne kadar yapılmış tüm çalışmaları gözden geçirdiğimiz bu derlemede değişen ve yenilenen bilgileri de katarak sonuçlar çıkarttık. HRT’ nin vasomotor semptomlar, vajinal atrofi ve osteoporoz üzerine olan olumlu etkileri yanında, HRT’ nin kronik bir hastalığı tedavi eder gibi kullanılmaması gerektiğini ortaya koyduk. HRT, menopozal semptomların tedavisi amacıyla, en düşük dozda, en az süreyle kullanılmalıdır.

🔖

Cite This Article

AZMAN, A., ÜNAL, E., GÜNEŞ, P., ÜNAL, A., KÖSE, G., TİTİZ, İ. (2022). The relationship between hormone replacement therapy (HRT) and breast cancer with reference to NIH-WHI and million women studies: Current reviev. Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 49 - Sayı: 1, 61–66. https://ajindex.com/articles/535516

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Kösebay D, Beşe T. Hormon replasman tedavisi ve meme kanseri ilişkisi. In: Unal G, Unal H. Meme Hastalıkları, Nobel Tıp Kitabevleri Ltd fiti, istanbul, 2001
  2. fiahmay S. Selim meme hastalıkları ve hormon replasman tedavisi. In: Unal G, Unal H. Meme Hastalıkları, Nobel Tıp Kitabevleri Ltd fiti, istanbul, 2001
  3. Soderqvist G, Schoultz B. Progestogen and breast epithelial proliferation. In: Studd J. The management of the menopause. The Parthenon Publishing Group, New York, 2000237-41. 4. Sitruk-Ware R, Plu-Bureau G. Progestogen use and breast cancer. In: Wren BG. Progress in the management of the menopause. TheParthenon Publishing Group, New York, 1997
  4. Topal NB, Ayhan S, Topal U, et al. Effects of hormone replacement therapy regimens on mammographic breast density: the role of progestins. J Obstet Gynaecol Res 2006
  5. Crouchley K, Wylie E, Khong E. Hormone replacement therapy and mammographic screening outcomes in Western Australia. J Med Screen 2006
  6. Gambrell RD. The menopause: benefits and risks of estrogen-progesteron replacement therapy. Fertil Steril 1982
  7. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Eng J Med 1995
  8. Ewertz M. Influence of non-contraceptive exogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988
  9. Sala E, Warren R, McCann J, et al. High-risk mammographic parenchymal patterns, hormone replacement therapy and other risk factors: a case-control study. Int J Epidemiol 2000
  10. Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacemnt therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmeno- pausal breast. J Clin Endocrinol Metab 1999
  11. Rohan TE, Miller AB. Hormone replacemnt therapy and risk of benign proliferative epithelial disorders of the breast. Eur J Cancer Prev 1999
  12. Cahn MD, Tran T, Theur CP, et al. Hormone replacement therapy and the risk of breast lesions that predispose to cancer. Am Surg 1997
  13. Dupont WD, Page DL, Parl FF, et al. Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 1999
  14. Korenman SG. Estrogen window hypothesis of the etiology of breast cancer. Lancet 1980
  15. Palmer JR, Rosenberg L, Clarke EA, et al. Breast cancer risk